Advertisement
Advertisement
U.S. markets open in 48 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Dicerna Pharmaceuticals, Inc. (DRNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
38.16-0.02 (-0.05%)
At close: 04:00PM EST
38.02 -0.14 (-0.37%)
Pre-Market: 08:42AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Intermediate-term KST

Intermediate-term KST

Previous Close38.18
Open38.16
Bid38.02 x 1800
Ask38.09 x 1000
Day's Range38.14 - 38.23
52 Week Range19.06 - 40.14
Volume2,777,656
Avg. Volume2,259,447
Market Cap2.973B
Beta (5Y Monthly)0.79
PE Ratio (TTM)N/A
EPS (TTM)-1.63
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.96
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DRNA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Dicerna Pharmaceuticals, Inc.
    Analyst Report: Alnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm also has 12 clinical programs across the following therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Additionally, up-front fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
Advertisement
Advertisement